melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-02. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Applied Biosystems is one of various brands under the Life Technologies brand of Thermo Fisher Scientific corporation. The brand is focused on integrated systems for genetic analysis, which include computerized machines and the consumables used within them (such as reagents). In 2008, a merger between Applied Biosystems and Invitrogen was finalized, creating Life Technologies. The latter was acquired by Thermo Fisher Scientific in 2014. Prior to 2008, the Applied Biosystems brand was owned by various entities in a corporate group parented by PerkinElmer. The roots of Applied Biosystems trace back to GeneCo (Genetic Systems Company), a pioneer biotechnology company founded in 1981 in Foster City, California. Through the 1980s and early 1990s, Applied Biosystems, Inc. operated independently and manufactured biochemicals and automated genetic engineering and diagnostic research instruments, including the principal brand of DNA sequencing machine used by the Human Genome Project consortium centers. Applied Biosystems' close ties to the consortium project led to the idea for the founding of Celera Genomics in 1998 as one of several independent competitors to the consortium. In 1993 Applied Biosystems, Inc., was delisted from the NASDAQ when it was acquired by the old company known then as Perkin-Elmer. As the PE Applied Biosystems Division under that parent in 1998, it became consolidated with other acquisitions as the primary PE Biosystems Division.
Lee, Nick; Bessho, Yoshitaka; Wei, Kenneth; Szostak, Jack W.; Suga, Hiroaki (2000). "Ribozyme-catalyzed tRNA aminoacylation". Nature Structural Biology. 7 (1): 28–33. doi:10.1038/71225. PMID 10625423. S2CID 1831912. Ramaswamy, Krishna; Saito, Hirohide; Murakami, Hiroshi; Shiba, Kiyotaka; Suga, Hiroaki (2004). "Designer Ribozymes: Programming the tRNA Specificity into Flexizyme". Journal of the American Chemical Society. 126 (37): 11454–11455. Bibcode:2004JAChS.12611454R. doi:10.1021/ja046843y. PMID 15366888. Passioura, Toby; Suga, Hiroaki (2017). "A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets". Chemical Communications. 53 (12): 1931–1940. doi:10.1039/C6CC06951G. PMID 28091672.
=== Gene mutations === Several gene mutations have been identified in patients with camptocormia. These include the RYR1 gene in axial myopathy, the DMPK gene in myotonic dystrophy, and genes related to dysferlinopathy and Parkinson's disease. These genes could serve as targets for gene therapy to treat the condition in the years to come.
Sources: en.wikipedia.org
=== RNA polymerase II === Proline isomerization of certain prolines in RNA polymerase II is key in the process of recruiting and placing processing factors during transcription. PPIases target RNA polymerase II by interacting with the Rpb1 carboxy terminal domain, or CTD. Proline isomerization is then used as part of the mechanism of the CTD to recruit co-factors required for co-transcriptional RNA processing, regulating RNA polymerase II activity. Nrd1 is a protein that is responsible for many of the transcriptional activities of RNAP II, specifically through the Nrd1- dependent termination pathway. This pathway requires the parvulin Ess1, or Pin1 depending on the organism, to isomerize the pSer5-Pro6 bond in the CTD. Without the cis conformation of the pSer5-Pro6 bond, created by Ess1/Pin1, Nrd1 cannot bind to RNAP II. Any variation from this process leads to a decrease in Nrd1 binding affinity, lowering the ability of RNAP II to process and degrade noncoding RNAs.
=== Expansion === In March 2020, many of the Cane's locations switched from dine-in to pick-up and take-out service only due to the COVID-19 pandemic, whereas others closed temporarily. As of July 2020, certain locations had reopened their dining rooms, although Graves said the company was in no rush to do so on a full scale. In 2021, in response to a shortage of workers at the time, the company began dispatching hundreds of its corporate employees to work in its restaurants as cooks and cashiers, in addition to their existing duties regarding the hiring of new employees. The company planned to hire 10,000 new employees. The company's co-CEO said that the corporate employees are trained in the kitchen and on the register under normal circumstances. In 2022, Raising Cane's sued a shopping center in Hobart, Indiana. After the restaurant chain had signed a long-term lease, it was revealed that the shopping center had a non-compete agreement with McDonald's which prohibited other vendors from selling de-boned chicken products in the complex. On June 27, 2023, Raising Cane's opened up their first New York location in Times Square.
== Internet == Freedom House's Freedom on the Net2018 gave Thailand a score of 65 (0=best, 100=worst) for internet freedom. Not one of the eight ASEAN nations listed in the report achieved a "free" rating. Best was the Philippines; worst was Vietnam. Freedom House: In 2015 awarded Thailand an overall score of 63 ("not free") (0=best, 100=worst) for Internet freedom in the calendar year 2014, ranking 50 of 65 countries. In 2013 Thailand was rated as "partly free". International Telecommunication Union (ITU): In their 2012 report, ranked Thailand 92 of 155 countries for telecommunications infrastructure. Ookla Speedtest: The company known for its popular Internet utility, Speedtest, ranked all nations for rolling mean download speed in Mbps (megabit per second) in May 2015. Rankings are based on throughput over the previous 30 days to servers not more than 480 km from the client computer. Thailand ranked 52nd of 200 nations (20 Mbit/s). Other ASEAN nations ranked were Singapore (1 of 200 nations) 122 Mbit/s; Vietnam (61 of 200) 20 Mbit/s; Cambodia (110 of 200) 9 Mbit/s; Brunei (116 of 200) 8 Mbit/s; Malaysia (130 of 200) 7 Mbit/s; Laos (133 of 200) 7 Mbit/s; Indonesia (139 of 200) 7 Mbit/s; Myanmar (140 of 200) 7 Mbit/s; and the Philippines (176 of 200) 4 Mbit/s. According to Romanian internet security software firm Bitdefender, Thailand ranked fifth of 25 Asian nations in quantity of internet malware detected. India, Indonesia, China, and Vietnam were the top four cyber-security risks in Asia.
Sources: en.wikipedia.org
To increase the level of recycling and meet its targets, Tetra Pak engaged in driving recycling activities such as developing collection schemes, launching new recycling technologies, and raising awareness of recycling and sustainability. Used Tetra Pak packages have been recycled as construction material in design projects, with varying results. By 2017, 25% of Tetra Pak cartons were recycled globally. At that time, the company announced that global recycling rates would no longer be one of its main metrics measured in sustainability reports, abandoning its previous target of increasing recycling rates to 40% by 2020, and instead introduced new metrics to measure against, such as public outreach, access to recycling facilities, and recycling capacity. In 2018, Tetra Pak signed an agreement with the environmental services company Veolia "to recycle all the components of used beverage cartons collected within the EU by 2025." Tetra Pak has also partnered with the Certified Renovated Equipment organization to refurbish old equipment so it can be resold as part of a circular economy initiative. In attempts to innovate and to improve the recyclability rate of their Aseptic cartons, one of the main factors is the replacement of the aluminum layer used, which can constitute up to 5% of the package material. In which, exposure to the metal has been suggested as a risk factor for Alzheimer's Disease. The company is currently testing two alternatives as a replacement for aluminum: (1) a fiber-based barrier layer, and (2) a polymer-based barrier.
Machaca – a dish prepared most commonly from dried, spiced beef or pork, then rehydrated and pounded to make it tender. The reconstituted meat would then be used to prepare any number of dishes. Meat extract – highly concentrated meat stock, usually made from beef. It is used to add meat flavor in cooking, and to make broth for drinking. Meat extracts have largely been supplanted by bouillon cubes and yeast extract.
=== Middle East === The Israeli military maintains an intricate network of internal border controls within the Israeli-occupied West Bank as well as external border controls between the West Bank and Israel, restricting the freedom of movement of Palestinians, composed of permanent, temporary, and random manned checkpoints in the West Bank; the West Bank Barrier; and restrictions on the usage of roads by Palestinians. Spread throughout the areas of the State of Palestine under de facto Israeli control, internal border control measures are a key feature of Palestinian life and are among the most restrictive in the world. Additionally, the blockade of the Gaza Strip results in a de facto domestic customs and immigration border for Palestinians. To clear internal border controls, Palestinians are required to obtain a variety of permits from Israeli authorities, depending on the purpose and area of their travel. The legality and impact of this network of internal border controls are controversial. B'Tselem, an Israeli non-governmental organisation that monitors human rights in Palestine, argues that they breach the rights guaranteed by the International Covenant on Economic, Social and Cultural Rights—in particular, the right to a livelihood, the right to an acceptable standard of living, the right to satisfactory nutrition, clothing, and housing, and the right to attain the best standard of physical and mental health.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.